Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria [0.03%]
抗菌肽在治疗多重耐药菌方面的研究进展
Yuanzhi Ju,Luxi Weng,Tiantian Lin et al.
Yuanzhi Ju et al.
Drug-resistant bacteria have become one of the greatest threats to human health in recent decades. With the large-scale abuse of antibiotics, bacteria resistant to traditional antibiotics are becoming increasingly common while clinical opti...
Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study [0.03%]
关于当前或既往患有癌症的银屑病患者使用瑞沙尼珠单抗的多中心回顾性真实世界研究
Marco Sousa,Ana Luísa João,Martim Luz et al.
Marco Sousa et al.
Courtney Chen,Jennifer Cillis,Supriya Deshpande et al.
Courtney Chen et al.
Oncolytic viruses (OVs) are naturally occurring or genetically modified viruses that selectively target cancer cells for infection, replication, and lysis. Specifically, their tumor tropism and promising antitumoral efficacy through direct ...
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis [0.03%]
monoclonal抗体治疗多发性硬化症的现状和未来
Silvia Susin-Calle,Elvira Munteis,Pablo Villoslada et al.
Silvia Susin-Calle et al.
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. Advances in understanding MS immunopathogenesis have led to the development of monocl...
Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation [0.03%]
针对B细胞自身免疫性肾病下一代CD20靶向治疗
Federico Yandian,Sanjeev Sethi,Fernando C Fervenza et al.
Federico Yandian et al.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malig...
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024 [0.03%]
欧盟2013年至2024年批准的上市后监管措施中的真实世界数据包含情况：基于先进治疗药品的案例研究
Diogo Almeida,Diana Mandslay,Peter G M Mol et al.
Diogo Almeida et al.
Background: Advanced therapy medicinal products (ATMPs) often require long-term monitoring to assess both safety and efficacy post-authorisation due to uncertainties identified during the approval process. This study aims...
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability [0.03%]
欧洲生物制药的引入：早期扩散模式和数据可用性的横断面研究
Ivar Veszelei,Brian Godman,Katri Aaltonen et al.
Ivar Veszelei et al.
Background and objectives: Biopharmaceuticals add value in the treatment of many diseases but different health systems in Europe face clinical and economic challenges with introducing them. Joint efforts across Europe are...
Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products [0.03%]
RGB-14-P和RGB-14-X生物类似药与denosumab参比制剂的全面理化及功能相似性评估研究
Ágnes Szonja Garai,Dániel Hüse,Ádám Fizil et al.
Ágnes Szonja Garai et al.
Background and objective: Denosumab is a fully human monoclonal antibody (IgG2) k subclass that targets and binds with high affinity and specificity to receptor activator of nuclear factor-κB ligand (RANKL). Gedeon Richt...
Comprehensive Physico-Chemical and Functional Similarity Assessment of Intravenous and Subcutaneous RGB-19 Drug Products as Proposed Biosimilars to Tocilizumab Reference Product [0.03%]
作为托珠单抗参比制剂的静脉注射和皮下注射RGB-19药物产品的全面理化及功能性相似性评估
Katalin Solti,Sarolta Timári,Tamás Faludi et al.
Katalin Solti et al.
Background and objective: Tocilizumab is a recombinant, humanised monoclonal antibody of the immunoglobulin G1 (IgG1) subclass, which specifically targets the interleukin-6 receptor (IL-6R). The RGB-19 product was develop...
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline [0.03%]
双特异性抗体在血液系统恶性肿瘤中的应用：攻击前线疗法
Toral Shastri,Asaad Trabolsi,Artavazd Arumov et al.
Toral Shastri et al.
Since blinatumomab's approval as the first bispecific antibody (BsAb) in cancer therapy, these immunomodulatory agents have achieved substantial success in lymphoid malignancies. A decade after provisional approval in relapsed settings, bli...